Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

18 Sept 2020

Abstract excerpt

Background: Endocrine therapy (ET) is the mainstay of treatment for hormone receptor positive HER2 negative metastatic breast cancer, however, adaptive mechanisms emerge in about 25-30% of cases through alterations in the estrogen receptor ligand-binding domain, with a consequent ligand-independent ER activity. Epigenetic-mediated events are less known and potentially involved in alternative mechanisms of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33072577
DOI: 10.3389/fonc.2020.550185

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast CancerPMID 33072577Read ↗

Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies.Semantic proximity Read ↗

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity Read ↗

ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.Semantic proximity Read ↗

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.Semantic proximity Read ↗

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read ↗

Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 PatientsSemantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.Semantic proximity Read ↗

Evolutionary Overview and Future Perspectives: ESR1 Mutations, Liquid Biopsy, and Artificial Intelligence for a New Era of Personalized Medicine in ER+ Breast Cancer.Semantic proximity Read ↗

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.Semantic proximity Read ↗

Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot StudySemantic proximity Read ↗

Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.